Full-Time

Senior Accountant / Sec Reporting Analyst

Posted on 4/5/2024

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops off-the-shelf genetically modified T cells

Biotechnology

Compensation Overview

$107,000 - $148,000Annually

+ Annual Cash Bonus + Long-Term Incentives (Equity) + Employee Stock Purchase Plan (ESPP)

Senior

San Carlos, CA, USA

Requirements
  • Bachelor's degree in Accounting or Finance
  • CPA preferred
  • Minimum of five years experience with Big 4 experience of at least 2-3 years, and public biotech/pharma industry experience of at least 2 years
  • In-depth knowledge of US GAAP, SEC reporting and SOX 404 compliance
  • Hands on experience with Active Disclosure preferred
  • Proficient with Microsoft Office (Outlook, Word, Excel, Powerpoint)
  • Experience with Dynamics Business Central
Responsibilities
  • Participate in monthly close process and ensure all responsible GL transactions are accounted for in accordance with U.S. GAAP
  • Prepare and book journal entries for month-end close, including updating balance sheet reconciliations and analyzing reconciling items
  • Interact with Accounting team members to ensure timely and accurate analysis and reconciliation of assigned general ledger accounts as well as understand financial transactions impacting financial reporting disclosures
  • Collaborate with our third party consulting firm to prepare the Company's stock-based compensation expense
  • Interact with our third party stock plan administrator regarding equity activity and updating Equity Edge Online
  • Assist in the preparation of quarterly consolidated financials (consolidated trial balance, balance sheet, income statement, cash flow statement) for external reporting purposes and quarterly reviews
  • Assist in the preparation of SEC filings and supporting documents, including Form 10-K, 10-Q, section 16 reporting, Form 4’s, Proxy Statement and other required filings
  • Maintain and update SOX documentation and audit schedules for quarterly reviews and annual audits
  • Focus on continuous process improvement initiatives that enhance the efficiency and accuracy of financial reporting
  • Special projects as requested

Adicet Bio, Inc is at the forefront of developing off-the-shelf genetically modified gamma delta T cells that specifically target tumors. By employing cutting-edge techniques like chimeric antigen receptors and T cell receptor-like antibodies, this biotechnology company is leading the way in enhancing selective tumor targeting and improving treatment persistence for long-lasting effects in patients. Working here offers an opportunity to be part of a pioneering team dedicated to groundbreaking biological research in cancer treatment, positively impacting patient outcomes in a supportive and innovative environment.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

6%

2 year growth

64%
INACTIVE